More opportunities for shingles protection with recombinant vaccine

+Practice
In print
VACCINES

More opportunities for shingles protection with recombinant vaccine

Ballpoint pen

Mary Nowlan

zoster vaccine efficacy graph
[Data from Strezova et al (Open Forum Infect Dis 2022;9(10):ofac485)]

This article reviews recent changes to the herpes zoster vaccine used in New Zealand, including recommendations for who should get vaccinated and when

Key points, Herpes zoster is a painful and potentially severe condition. The risk of post-herpetic neuralgia increases with age. Two doses of Shingrix are hig, Pract Green w Pale Yellow
References
  • Bhavsar A, Lonnet G, Wang C, et al. Increased risk of herpes zoster in adults ≥50 years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis 2022;9(5):ofac118.
  • Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. NEJM 2016;375(11):1019–32.
  • Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (Shingrix): Real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis 2021;73(6):941–48.
  • Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. NEJM 2015;372(22):2087–96.
  • Oostvogels L, Heineman TC, Johnson RW, et al. Medical conditions at enrolment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vacc Immunother 2019;15(12):2865–72.
  • Racine E, Gilca V, Amini R, et al. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49-year-old patients. Vaccine 2020;38(40):6205–14.

Figure data from: Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis 2022;9(10):ofac485.